InterMune: Time to go global

Companies with clinical development experience are constantly trolling for compounds they can in-license to leverage those capabilities, but the market for quality compounds is tight.

InterMune Pharmaceuticals Inc. last week put a twist on this search by leveraging its ongoing clinical development program for Actimmune interferon gamma-Ib to

Read the full 487 word article

How to gain access

Continue reading with a
two-week free trial.